Significance of verification of IVUS-guided stent optimisation by �솉紐낃린 & �솉�꽦吏�
The opinions expressed in this article are not necessarily those of the Editors of AsiaIntervention.
7
E D I T O R I A L
A
siaIntervention 2
0
1
8
;4
:7-9   
D
O
I: 10
.4
2
4
4
/A
IJV4
I1
A
2
© Europa Digital & Publishing 2018. All rights reserved.
*Corresponding author: Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 
50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea. E-mail: mkhong61@yuhs.ac
Significance of verification of IVUS-guided stent optimisation
Sung-Jin Hong1, MD; Myeong-Ki Hong1,2*, MD, PhD
1. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, South Korea; 
2. Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, South Korea
During percutaneous coronary intervention (PCI), intravascu-
lar ultrasound (IVUS) provides anatomic information for the 
coronary artery lumen, wall, and plaques, which can help the 
accurate evaluation of the lesion with vessel sizing1. Moreover, 
post-PCI stent underexpansion, malapposition, or edge dis-
sections can be detected for stent optimisation, resulting in 
improved clinical outcomes1-4. Recently, much evidence dem-
onstrating the clinical usefulness of IVUS has become avail-
able, particularly for complex lesions, such as left main disease, 
chronic total occlusions, and diffuse long lesions2-4. According 
to the recent large randomised study of the IVUS-XPL (Impact 
of Intravascular Ultrasound Guidance on Outcomes of Xience 
Prime Stents in Long Lesions) trial, IVUS-guided drug-eluting 
stent (DES) implantation, particularly for diffuse long lesions, 
compared with angiography-guided DES implantation resulted 
in a significantly lower rate of the composite endpoint of major 
adverse cardiac events (a composite of cardiac death, myocardial 
infarction, or target lesion revascularisation) at one year (2.9% 
vs. 5.8%, hazard ratio [HR] 0.48, p=0.007)2. These differences 
were primarily due to a lower risk of target lesion revasculari-
sation (2.5% vs. 5.0%, HR 0.51, p=0.02). Also, the results of 
a meta-analysis with individual patient-level data from 2,345 
randomised patients showed that IVUS-guided new-genera-
tion DES implantation vs. angiography-guided DES implanta-
tion was associated with a favourable outcome, particularly the 
occurrence of the hard clinical endpoint (the composite of car-
diac death, myocardial infarction, or stent thrombosis) for com-
plex lesions3. Of note, the primary endpoint of this meta-analysis 
did not include target lesion revascularisation. Therefore, dif-
ferent from the IVUS-XPL trial showing the benefit of IVUS 
due primarily to less frequent TLR events2, major adverse car-
diac events, even excluding the target lesion revascularisation 
events in this meta-analysis, were less frequent with IVUS guid-
ance than with angiography guidance3. Lastly, according to the 
ADAPT-DES (Assessment of Dual AntiPlatelet Therapy With 
Drug Eluting Stents) study, the largest all-comers observational 
study (n=8,583)5, IVUS was utilised in 3,349 patients (39%), and 
larger-diameter devices, longer stents, and/or higher inflation 
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pressure were used in the IVUS-guided cases. At one year, pro-
pensity-adjusted multivariable analysis revealed that IVUS guid-
ance vs. angiography guidance was associated with reduced 
definite/probable stent thrombosis (0.6% vs. 1.0%, p=0.003), 
myocardial infarction (2.5% vs. 3.7%, p=0.004), and a compos-
ite of adjudicated major cardiac events (cardiac death, myocar-
dial infarction, or stent thrombosis) (3.1% vs. 4.7%, p=0.002). 
The benefits of IVUS were especially evident in patients with 
acute coronary syndromes and complex lesions5.
Contrary to these findings2-5, in this issue of AsiaIntervention, 
Watanabe et al in their study failed to demonstrate the clinical use-
fulness of IVUS guidance for target vessel revascularisation in the 
patients treated with first-generation DES6.
Article, see page 26
They sought to evaluate the clinical impact of IVUS use in first-
generation DES implantation from the Coronary REvascularisation 
Demonstrating Outcome study in Kyoto (CREDO-Kyoto) PCI/
CABG registry cohort-2. As a retrospective cohort study, they 
selected the patients treated with first-generation DES without 
acute myocardial infarction, and compared clinical outcomes 
between the two groups of patients with or without IVUS use 
(IVUS-guided group [n=2,768] vs. angiography-guided group 
[n=2,000]). There was no significant difference between the 
groups in the cumulative incidence of target vessel revasculari-
sation (21.5% vs. 22.2%, p=0.57). Even after adjustment for 
confounders, the risk of IVUS guidance relative to angiography 
guidance for target vessel revascularisation remained neutral (HR 
1.09, 95% CI: 0.90-1.32, p=0.37). Thus, they concluded that 
IVUS-guided PCI as compared with angiography-guided PCI was 
not associated with a lower risk for target vessel revascularisation 
in patients treated with first-generation DES.
Failure to demonstrate the clinical usefulness of IVUS-guided 
DES implantation in this study might be attributed to the follow-
ing reasons. First, the definition of IVUS usage was too obscure. 
They did not differentiate the use of IVUS according to the tim-
ing of IVUS examination, and included the IVUS usage for 
pre-stent deployment, post-stent deployment, or both strategies. 
Thus, the effect of IVUS usage particularly for stent optimisa-
tion, which can be most important during PCI, was not accu-
rately addressed. According to the previous IVUS-XPL trial1, 
even among the patients with IVUS guidance, the clinical out-
comes were totally different between the patients meeting the 
IVUS criteria for stent optimisation and those who did not meet 
the IVUS criteria (1.5% vs. 4.6%; HR 0.31, 95% CI: 0.11-0.86, 
p=0.02). Thus, the study evaluating the clinical efficacy of IVUS 
requires appropriate analyses of the measurements of IVUS para-
meters after DES implantation. Moreover, the lack of analyses of 
IVUS parameters raises the question of the extent to which the 
stent optimisation by IVUS was achieved in the IVUS-guided 
group. It is not a simple matter of usage or non-usage of IVUS, 
but whether the improvement of clinical outcomes is accompa-
nied by “appropriate use of IVUS”, i.e., the extent of stent opti-
misation by IVUS usage. The interpretation of IVUS images 
is not intuitive, but requires a careful understanding of what is 
important1. Second, this study was not a randomised study but 
an observational study with a modest sample size. Third, the 
authors only included patients treated with first-generation DES, 
which are not widely used in current practice. Fourth, in this 
study, all-comers treated with DES were included. Patients with 
chronic total occlusions were only 15.9% in the IVUS group, and 
the proportion of patients with a larger than 28 mm stent was 
52.8%. However, rather than routine use of IVUS for stent opti-
misation, IVUS usage (particularly for complex lesions) could 
be more beneficial. Although they tried subgroup analyses, the 
number of patients could be too small to detect the clinical effi-
cacy of IVUS for each subgroup, something which was different 
from the previous ADAPT-DES study5.
However, it is notable that there was a trend towards a bene-
ficial effect in small vessels in subgroup analyses, indicating the 
beneficial effect of IVUS particularly for small vessels. Also, the 
final balloon pressure was statistically greater in the IVUS group 
at 20 atm vs. 18 atm (p<0.0001), although the authors did not 
include the analyses of quantitative coronary angiography after 
stent implantation, which would be essential to confirm the dif-
ferences in angiographic results between the two groups. Lastly, 
although the authors failed to demonstrate the superiority of the 
IVUS-guided group for target vessel revascularisation, the superi-
ority of the IVUS-guided group was observed for all-cause death 
(HR 0.85, 95% CI: 0.73-0.99, p=0.04), myocardial infarction 
(HR 0.75, 95% CI: 0.59-0.95, p=0.02), and major adverse cardiac 
events (HR 0.88, 95% CI: 0.79-0.97, p=0.01) for the propensity 
score-matched cohort.
Taken together, the present study provides valuable lessons 
in terms of (i) the importance of appropriate IVUS usage in 
selected patients rather than routine usage along with appro-
priate interpretation of the IVUS images1, (ii) the necessity 
of well-designed randomised trials, (iii) the need for cautious 
interpretation of negative findings of retrospective analyses 
with modest sample sizes, and (iv) the requirement for ana-
lyses of the parameters of quantitative coronary angiography 
and IVUS measurements.
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
 1. Mintz GS, Guagliumi G. Intravascular imaging in coronary 
artery disease. Lancet. 2017;390:793-809.
 2. Hong SJ, Kim BK, Shin DH, Nam CM, Kim JS, Ko YG, 
Choi D, Kang TS, Kang WC, Her AY, Kim YH, Hur SH, Hong BK, 
Kwon H, Jang Y, Hong MK; IVUS-XPL Investigators. Effect of 
intravascular ultrasound-guided vs angiography-guided everoli-
mus-eluting stent implantation: The IVUS-XPL randomized clini-
cal trial. JAMA. 2015;314:2155-63.
 3. Shin DH, Hong SJ, Mintz GS, Kim JS, Kim BK, Ko YG, 
Choi D, Jang Y, Hong MK. Effects of intravascular ultrasound-
9IVUS-guided stent optimisation
A
siaIntervention 2
0
1
8
;4
:7-9
guided versus angiography-guided new-generation drug-eluting 
stent implantation: meta-analysis with individual patient-level data 
from 2,345 randomized patients. JACC Cardiovasc Interv. 2016;9: 
2232-2239.
 4. Ye Y, Yang M, Zhang S, Zeng Y. Percutaneous coronary inter-
vention in left main coronary artery disease with or without intra-
vascular ultrasound: A meta-analysis. PLoS One. 2017;12:e0179756.
 5. Witzenbichler B, Maehara A, Weisz G, Neumann FJ, 
Rinaldi MJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Brodie BR, 
Stuckey TD, Mazzaferri EL Jr, Xu K, Parise H, Mehran R, 
Mintz GS, Stone GW. Relationship between intravascular ultra-
sound guidance and clinical outcomes after drug-eluting stents: the 
assessment of dual antiplatelet therapy with drug-eluting stents 
(ADAPT-DES) study. Circulation. 2014;129:463-70.
 6. Watanabe H, Morimoto T, Shiomi H, Furukawa Y, 
Nakagawa Y, Ando K, Kadota K, Kimura T; the CREDO-Kyoto 
PCI/CABG registry investigators. Intravascular ultrasound-guided 
versus angiography-guided percutaneous coronary intervention 
with drug-eluting stents: five-year outcomes from the CREDO-
Kyoto PCI/CABG registry. AsiaIntervention. 2018;4:26-33.
